Recursion Pharmaceuticals (RXRX) Other Non-Current Assets (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Other Non-Current Assets data on file, last reported at $5.2 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 7.69% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 7.69% YoY) and the FY2025 annual result came in at $6.0 million, down 31.64% from the prior year.
• Other Non-Current Assets eased to $5.2 million in Q1 2026, from $6.0 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $9.4 million in Q2 2025 to a low of $36000.0 in Q1 2022.
• A 5-year average of $6.1 million and a median of $6.6 million in 2023 frame the typical range for Other Non-Current Assets.
• The widest YoY moves for Other Non-Current Assets: up 23197.14% in 2022, down 98.83% in 2022.
• Tracing RXRX's Other Non-Current Assets over 5 years: stood at $7.9 million in 2022, then declined by 16.3% to $6.6 million in 2023, then surged by 33.13% to $8.8 million in 2024, then slumped by 31.64% to $6.0 million in 2025, then declined by 13.87% to $5.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $5.2 million (Q1 2026), $6.0 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.